12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AT-101: Interim Phase II data

Data from 43 evaluable patients in an ongoing, open-label Phase II trial showed that AT-101 produced 1 partial response and 8 cases of stable disease. Progression free survival ranged...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >